Gut bacteria could be key to better cancer immunotherapy

NCT ID NCT07236983

Ongoing Knowledge-focused Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how the diversity of bacteria in the gut might affect how well immunotherapy works in people with solid tumors. Researchers will collect stool and blood samples from 70 cancer patients starting immunotherapy to track changes in gut bacteria and immune markers. They also want to see if diet, especially a Mediterranean diet, plays a role. The goal is to better understand why some patients respond to immunotherapy while others do not.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help identify ways to improve immunotherapy effectiveness by modifying gut bacteria through diet or other means.
What could go wrong: This is an early observational study with only 70 participants, so results may not apply to all patients. It looks at patterns, not direct treatment effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR CANCER TREATMENT WITH IMMUNOTHERAPY

Contacts and locations

Show contact details

Locations

Fondazione IRCCS Policlinico San Matteo, SC Oncologia

Pavia, Pavia, 27100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.